首页> 外文期刊>Pharmaceutical Biology >In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes
【24h】

In vitro inhibitory effects of kaempferitrin on human liver cytochrome P450 enzymes

机译:山楂铁蛋白对人肝细胞色素P450酶的体外抑制作用

获取原文
       

摘要

Context: Kaempferitrinis (KF) is a bioactive flavonoid and possesses numerous pharmacological activities. However, whether KF affects the activity of human liver cytochrome P450 (CYP) enzymes remains unclear. Objective: This study investigates the effects of KF on eight major CYP isoforms in human liver microsomes (HLMs). Materials and methods:In vitro, HLMs were used to investigate the inhibitory effects of KF (100?μM) on the eight human liver CYP isoforms (i.e., 1A2, 3A4, 2A6, 2E1, 2D6, 2C9, 2C19, and 2C8), and corresponding probe substrates were used. Enzyme kinetic studies (0-50?μM of KF) were conducted to determine the inhibition mode of KF on CYP enzymes. Results: The results showed that KF inhibited the activity of CYP1A2, 3A4, and 2C9, with IC50 values of 20.56, 13.87, and 14.62?μM, respectively, but that other CYP isoforms were not affected. Enzyme kinetic studies showed that KF was not only a noncompetitive inhibitor of CYP3A4, but also a competitive inhibitor of CYP1A2 and 2C9, with Ki values of 7.11, 10.24, and 7.58?μM, respectively. In addition, KF is a time-dependent inhibitor for CYP3A4 with KI/Kinact value of 10.85/0.036?min/μM. Discussion: The in vitro studies of KF with CYP isoforms indicate that KF has the potential to cause pharmacokinetic drug interactions with other co-administered drugs metabolized by CYP1A2, 3A4, and 2C9. Conclusion: It is recommended that KF should not be used with other drugs metabolized by CYP1A2, 3A4, and 2C9. Further clinical studies are needed to evaluate the significance of this interaction.
机译:背景:剑兰(Kempferitrinis)(KF)是一种具有生物活性的类黄酮,具有许多药理活性。但是,KF是否会影响人类肝脏细胞色素P450(CYP)酶的活性仍不清楚。目的:本研究调查KF对人肝微粒体(HLMs)的八种主要CYP亚型的影响。材料和方法:在体外,HLMs用于研究KF(100?μM)对八种人肝CYP亚型(即1A2、3A4、2A6、2E1、2D6、2C9、2C19和2C8)的抑制作用,使用相应的探针基底。进行了酶动力学研究(KF为0-50?M),以确定KF对CYP酶的抑制方式。结果:结果显示KF抑制CYP1A2、3A4和2C9的活性,IC50值分别为20.56、13.87和14.62?M,但其他​​CYP亚型不受影响。酶动力学研究表明,KF不仅是CYP3A4的非竞争性抑制剂,还是CYP1A2和2C9的竞争性抑制剂,Ki值分别为7.11、10.24和7.58?μM。此外,KF是CYP3A4的时间依赖性抑制剂,KI / Kinact值为10.85 / 0.036?min /μM。讨论:KF与CYP亚型的体外研究表明,KF有可能与其他由CYP1A2、3A4和2C9代谢的共同给药药物发生药代动力学药物相互作用。结论:建议不要将KF与经CYP1A2、3A4和2C9代谢的其他药物一起使用。需要进一步的临床研究来评估这种相互作用的重要性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号